Discussion  by unknown
these techniques to their armamentarium in the treatment of
lung neoplasms. In conclusion, RFA appears safe in high-
risk patients with stage I NSCLC, with reasonable results in
patients who are not fit for surgical intervention.
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Discussion
Dr Donald E. Low (Seattle, Wash). Dr Millien, Dr Sintek, mem-
bers, and guests, thank you very much. I appreciate the opportunity
of discussing this article. I also would like to thank the authors for
getting me the manuscript immediately before the meeting for
review.
This article describes RFA treatment of 19 patients with stage
I disease. All patients were reviewed by thoracic surgeons and
were deemed inoperable on medical grounds. The authors should
be congratulated in that surgeons not only carried out the assess-
ment of these patients but also delivered the actual RFA therapy in
the operating room. This is the third publication from your group
examining RFA therapy in different patient populations. Your first
study in 2003 examined 18 patients, 5 of whom had NSCLC. The
next report in 2005 reported 18 patients, all of whom had NSCLC,
but 50% had stage I disease. Clearly you are beyond the point of
studying the feasibility of RFA in lung cancer and at a point where
the focus should be on results, development of criteria for appli-
cation of RFA, and, just as importantly, redefinition of criteria for
medical inoperability. With that in mind, I believe that in a study
of patients with true stage I disease, we should be very careful
about opening the door to any nonsurgical approach, except in very
carefully documented circumstances. Lung volume reduction sur-
gery has taught us that pulmonary function tests are not the
absolute limiting factor about who can undergo surgical interven-
tion. Fifteen of 19 patients in your series were considered inoper-
able on the basis of “poor pulmonary function test results.” How-
ever, the only objective indication you documented in your article
was mean and median FEV1. Although it is reassuring that all of
your patients were reviewed by thoracic surgeons, your current
report would seem to provide excessive leeway for nonsurgeons to
designate patient as nonsurgical candidates.
Do you not believe that at a minimum you should provide more
specifics regarding predictable FEV1 and diffusion capacity in
identifying persons who are inoperable on the basis of pulmonary
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function test results? In addition, should your conclusions not
include a strong statement that short of being in a clinical trial,
patients with stage I disease should always be seen by experienced
thoracic surgeons and be presented in a multidisciplinary tumor
board before being relegated to RFA therapy?
Dr Pennathur. Those are all valid points, and I think that one
of the main issues regarding RFA is that there is not enough
follow-up evaluating long-term results in the literature. In a recent
review of the literature, most studies were case series with very
poor follow-up and minimal information on how the recurrence
was determined and the nature of the long-term results. That is one
of the reasons why we wanted to and continue to study this more
rigorously.
In terms of pulmonary function tests, our protocol comprises
basically a predicted postoperative FEV1 value of less than 40% as
one of the criteria. We use several criteria, with a complete
assessment of the patient. Pulmonary function test results alone are
not the sole criterion. The median FEV1 of these patients was 0.6,
and these were elderly patients (median age, 78 years) who had
multiple comorbidities. One of the measures of comorbidity that
we assessed was the Charlson Comorbidity Score, which takes into
consideration literally 19 conditions. It has been validated in
several cancers and now has also been validated in lung cancer. In
one study, in which the index was divided into categories of 0, 1
to 2, 3 to 4, and the worst at greater than 5, an index of greater than
3 to 4 was shown to be significantly associated with an increase in
postoperative complications. The mean Charlson Comorbidity
Score in our group of patients as a whole was greater than 5. I
share your concern that if these patients are not evaluated by
thoracic surgeons and instead evaluated by others making the
decision on inoperability, that is not right for the patient. As you
pointed out, with the benefits of lung volume reduction surgery,
these patients have to be evaluated by a thoracic surgeon, regard-
less of whether the patient is in a clinical trial, and we take into
consideration not mere numbers but several other factors before
we decide whether the patient is operable. In this series all patients
were seen and evaluated by thoracic surgeons before performing
RFA.
Dr Low. Just a comment before I go on to question 2, then. I
would encourage you to solidify and make much more distinct the
criteria that you are using for medical inoperability in your article.
The second question concerns the patient selection section of
your article, which indicates that “most patients had PET scans.”
Do you think that PET scans should routinely be a component of
the pretreatment assessment of these patients? Also, did all of these
patients undergo pretreatment CT-guided biopsies to confirm a
diagnosis before RFA therapy?
Dr Pennathur. Those are all excellent questions. This study
went on over a period of 3½ years. Early on, PET scans were not
routinely approved by insurance companies, and subsequently they
were approved. Yes, I think a PET scan should be a part of the
evaluation of these patients routinely. In this series 80% of the
patients had a PET scan.
Regarding your second question, everybody had a CT-guided
biopsy, and some of them were performed by the surgeon himself
before the RFA. The tissue diagnosis was confirmed to be NSCLC
in 18 of these patients, and in 1 patient it was called highly
suspicious. Clinically, this patient had a suspicious lesion that was
highly PET active, and with a suspicious call, we went ahead with
RFA, but everybody else had a clear documentation of NSCLC.
Dr Low. Your report states that 6 patients died, with a median
follow-up of 13.5 months. How many of these deaths were cancer
related?
Dr Pennathur. That is again a good question. We have not
actually analyzed that as cancer specific versus noncancer specific.
Several of the patients did not die at the University of Pittsburgh,
and on preliminary review and discussion with the primary phy-
sician, it appears that at least some of these were not cancer
related, and we are in the process of ascertaining these data.
Dr Low. Your study demonstrates that pneumothoraces were
immediate complications in 63% of your cases, although only 1
patient required a chest tube for greater than 4 days. Your main
competition for localized nonsurgical treatment for stage I lung
cancer is, of course, stereotactic radiation, which does not require
any treatment-related intrathoracic instrumentation and can be
used for more central tumors than those to which you have applied
RFA in your series. Current reports of stereotactic radiation indi-
cate local control rates of up to 80% to 90% at 1 and 2 years.
Specifically, what do you see as the major advantages of RFA over
stereotactic radiation?
I would like to thank the association for the opportunity to
discuss this article.
Dr Pennathur. Again, an excellent point. I think that SRS and
RFA could be potentially used in the same group of patients and in
fact can be used in a complementary fashion. We do not use RFA
for central lesions because of the proximity of the pulmonary
artery and the bronchus, and therefore this is primarily applicable
for peripheral lung tumors. Stereotactic radiosurgery (SRS) can be
used for central lung lesions, although at a decreased dose. In
terms of the analysis of the results of SRS, I have not found
anything in the United States with long-term follow-up. That is one
of the reasons we are studying SRS very closely. One of the few
publications in the United States was by Dr Richard Whyte, a
multicenter trial, and the other publication was from Dr Timmer-
man. He reported a total of 37 patients with stage I NSCLC,
inoperable patients. Median follow-up was 14 months, and the
15-month overall survival was 65%; therefore I do not see the data
as mature enough to comment on SRS in the United States.
Similarly, we have also reported our initial experience with SRS
with a median follow-up of 15 months. There are more data
available in Japan, but the experience in the United States, I think,
is still evolving. That is one of the things that we really want to
study. I think there might be a complementary role for SRS in
combination with RFA.
Dr Harold Urschel (Dallas, Tex). Thank you, Dr Pennathur.
That was a very nice presentation. How about making a comment
on the Cyberknife, the linear accelerator with the robot that actu-
ally treats the same kind of lesions, including now, hopefully,
central lesions and comparing it with the possibility—we are in the
Stanford, Pittsburgh, Dallas, Georgetown, and Boston group—of
trying to find these cases with what we think is a better approach.
What do you think about that?
Dr Pennathur. Thank you for your comments. I think Cy-
berknife is one of the 3 available pieces of equipment by which we
can deliver SRS and is a frameless system. In the United States I
think we have only a fair experience with stereotactic surgery. One
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point I want to mention that Dr Low alluded to earlier was the need
for thoracic procedures, which is also required for SRS; that is, you
have to place fiducials to mark and track the tumor for SRS. When
placing fiducials, you need typically about 3 to track the tumor. In
our institution we place these fiducials with CT guidance, and we
do the treatment planning with radiation oncology before SRS
also. The fiducials are not benign. We need to place the coaxial
needle about 3 times or so in the lung and place the fiducials. I
cannot remember the percentages, but there is a significant inci-
dence of pneumothorax with the placement of fiducials. For the
more central lesions, we might be able to perform the fiducial
placement with the bronchoscope in the future and that might
avoid some of the pneumothorax complications, but at the mo-
ment, we are doing percutaneous CT-guided fiducials, which do
cause pneumothoraces. I think in this area the multicenter trial we
have with Dr Urschel, Dr Whyte, and Georgetown-Boston is going
to be very important in answering some of the questions in terms
of SRS, patient selection, and evaluation of long-term results.
Unlike RFA, in which the complications you see are within the
first month typically, with SRS, particularly for central lesions, you
see complications, such as bronchial stenosis and so forth, months
and sometimes more than a year later down the road because of the
effects of radiation with fibrosis. Therefore I think more long-term
studies are required for us to really define the role of which patient
might be more suitable for SRS versus RFA and whether there is
a complementary role to using both of them.
Dr Eric Vallieres (Seattle, Wash). I appreciated your study and
Don’s and everyone else’s comments. I think in the future when
you are going to compare these various modalities you are going
to have to include cost. Radiation tools are not free. I think you are
going to have to include hospital stay and how many treatments
they need. This is a 1-day treatment. If your patient does not have
any complications, when do you send him home? What is your
hospitalization time on these?
Dr Pennathur. Thank you for your comments and questions.
The median hospital stay for us was 3 days. This patient group was
elderly, with multiple comorbidities, and we admitted almost all of
them. There is usually a zone of inflammation after the RFA, and
some have a pigtail catheter for the pneumothorax. Typically, we
admit them for a couple of days or so and then send them home.
Dr Vallieres. I think all of these factors are going to have to
weigh in because you know most of these folks die of their
noncancer; that is, they have a noncancer death. They die of their
comorbidities, and therefore really what it is going to come down
to is cost and how quickly you can deliver the treatment and get
them home.
Dr Pennathur. I think that is an excellent point. Costwise I
think the Cyberknife and the SRS are quite expensive, and the
institution has to invest the money in that. When you place
fiducials and if the patient has a pneumothorax, we admit them,
and that requires a few days’ hospitalization; then the patient
comes back for the radiosurgery, which is usually done as an
outpatient. With SRS, however, typically it is only 3 days as
opposed to the 6 weeks of treatment that is required for conven-
tional radiation.
I thank the Association for the privilege of presenting this
paper.
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